glp 1 market share GLP-1 Agonists Weight Loss Drugs Report, 2025-2030 Market Overview: GLP-1 Agonists and

doi: 10.1038/s41598-021-89166-8 76 FogelsonKADorresteinPCZarrinparAKnightR

Most large observational studies and clinical trials have not demonstrated a clear increase in medullary thyroid carcinoma among GLP-1 users

For endurance sports such as swimming, triathlons, marathons, skiing, and cycling, success depends not only on the athletes cardiovascular and muscular capacities but also on their energy metabolism (Li et al

Madsen, S

doi:10.1034/j.1600-0528.2001.290406.x

The Efficacy Gap: Oral vs Injectable Injectable tirzepatide (Zepbound), a dual GLP-1 and GIP receptor agonist, produced weight reductions of between 16% and 22.5% over 72 weeks in the SURMOUNT trials